Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rolf Stahel

Showing results (31-40 of 82) with videos related to

Pageof 9
Sort By:
Critical Reviews in Oncology/Hematology|January 11, 2020
Changing the education paradigm in oncology: ESO masterclass, 17 years of continuous successNicholas Pavlidis, Fedro Peccatori, Matti Aapro, et al.
Lung Cancer (Amsterdam, Netherlands)|December 21, 2007
TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8Larisa L Belyanskaya, Algirdas Ziogas, Sally Hopkins-Donaldson, et al.
Carcinogenesis|July 7, 2011
Pleural mesothelioma side populations have a precursor phenotypeClaudia Frei, Isabelle Opitz, Alex Soltermann, et al.
Neoplasia (New York, N.Y.)|July 27, 2006
p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesotheliomaSally Hopkins-Donaldson, Larisa L Belyanskaya, Ana Paula Simões-Wüst, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2011
Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meetingCesare Gridelli, Rolf Stahel, Benjamin Besse, et al.
Interactive Cardiovascular and Thoracic Surgery|April 29, 2017
Propensity matched comparison of extrapleural pneumonectomy and pleurectomy/decortication for mesothelioma patientsArthur Kostron, Martina Friess, Ilhan Inci, et al.
Clinical Lung Cancer|September 3, 2011
Can we customize chemotherapy? Individualizing cytotoxic regimens in advanced non-small-cell lung cancerRafael Rosell, Christian Manegold, Teresa Moran, et al.
Cancer Treatment Reviews|January 6, 2017
Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic reviewStephanie G C Kroeze, Corinna Fritz, Morten Hoyer, et al.
Plos One|October 1, 2015
Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor PrognosisSvenja Thies, Martina Friess, Lukas Frischknecht, et al.
Lung Cancer (Amsterdam, Netherlands)|February 1, 2011
Bioluminescence imaging for in vivo monitoring of local recurrence mesothelioma modelYandong Shi, Andreas Hollenstein, Emanuela Felley-Bosco, et al.
Pageof 9

Showing results (31-40 of 82) with videos related to

Sort By:
Pageof 9
Critical Reviews in Oncology/Hematology|January 11, 2020
Changing the education paradigm in oncology: ESO masterclass, 17 years of continuous successNicholas Pavlidis, Fedro Peccatori, Matti Aapro, et al.
Lung Cancer (Amsterdam, Netherlands)|December 21, 2007
TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8Larisa L Belyanskaya, Algirdas Ziogas, Sally Hopkins-Donaldson, et al.
Carcinogenesis|July 7, 2011
Pleural mesothelioma side populations have a precursor phenotypeClaudia Frei, Isabelle Opitz, Alex Soltermann, et al.
Neoplasia (New York, N.Y.)|July 27, 2006
p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesotheliomaSally Hopkins-Donaldson, Larisa L Belyanskaya, Ana Paula Simões-Wüst, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2011
Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meetingCesare Gridelli, Rolf Stahel, Benjamin Besse, et al.
Interactive Cardiovascular and Thoracic Surgery|April 29, 2017
Propensity matched comparison of extrapleural pneumonectomy and pleurectomy/decortication for mesothelioma patientsArthur Kostron, Martina Friess, Ilhan Inci, et al.
Clinical Lung Cancer|September 3, 2011
Can we customize chemotherapy? Individualizing cytotoxic regimens in advanced non-small-cell lung cancerRafael Rosell, Christian Manegold, Teresa Moran, et al.
Cancer Treatment Reviews|January 6, 2017
Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic reviewStephanie G C Kroeze, Corinna Fritz, Morten Hoyer, et al.
Plos One|October 1, 2015
Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor PrognosisSvenja Thies, Martina Friess, Lukas Frischknecht, et al.
Lung Cancer (Amsterdam, Netherlands)|February 1, 2011
Bioluminescence imaging for in vivo monitoring of local recurrence mesothelioma modelYandong Shi, Andreas Hollenstein, Emanuela Felley-Bosco, et al.
Pageof 9